First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer (Q26471909)

2

0 references

Angela Boland

3

0 references

Victoria Bates

4

0 references

Fabio Vecchio

5

0 references

Yenal Dundar

6

0 references

Pooja Jain

7

0 references

John A Green

Cochrane Database of Systematic Reviews

8

0 references

publication date

25 May 2016

0 references

published in

0 references

cites work

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Progression-free survival: meaningful or simply measurable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet che

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010383.PUB2